指南与共识神经肿瘤

胶质瘤类器官模型:分类、保真度与转化神经肿瘤学指南

Modeling gliomas with organoids: Classification, fidelity, and guidelines for translational neuro-oncology.
指南 / 共识 · Neuro Oncol · 2026-01-01

该综述系统梳理了胶质瘤类器官模型的三大类别(工程化类器官、患者来源类器官、组装体),强调不同模型各有互补优势,并提出基础命名框架以减少术语碎片化。文章还讨论了IDH突变胶质瘤和弥漫性中线胶质瘤等挑战性亚型的应用,以及可扩展性、标准化、微环境保真度和血管化等关键挑战,呼吁加强协作与标准化以加速类器官模型融入转化研究流程。

要点

  • 胶质瘤类器官分为工程化、患者来源和组装体三类,各有互补优势。
  • 患者来源类器官保留原肿瘤关键分子和组织病理学特征。
  • 提出基础命名框架以改善领域内术语清晰度和交流。

核心结论

  • 胶质瘤类器官模型可为人细胞相关框架研究胶质瘤生物学、肿瘤微环境交互及治疗反应与耐药提供平台。

研究设计与样本

  • 综述类文章,检索范围未在摘要中报告。

主要发现

  • 工程化类器官可对特定突变驱动的胶质瘤发生进行受控建模。
  • 患者来源类器官保留原肿瘤的关键分子和组织病理学特征。
  • 组装体设计用于模拟肿瘤-微环境相互作用。
  • 类器官模型应用于IDH突变胶质瘤和弥漫性中线胶质瘤(DMG)等技术挑战性亚型。
  • 关键挑战包括可扩展性、标准化、微环境保真度和血管化。

关键数值与推荐

  • 提出胶质瘤类器官模型的基础命名框架以改善领域内清晰度和交流。

临床怎么用

  • 根据具体基础和转化研究目标选择适当的类器官模型和分析读数。
  • 利用类器官平台研究胶质瘤生物学、微环境串扰及治疗反应与耐药。

局限性

  • 方法学异质性和术语碎片化日益增加。
  • 可扩展性、标准化、微环境保真度和血管化等关键挑战尚待解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in organoid technology have transformed how gliomas are modeled and studied. Recent FDA and NIH initiatives further promote human-relevant organoid platforms for preclinical research. Glioma organoids can be broadly categorized into 3 main classes: Engineered organoids, which enable controlled modeling of gliomagenesis driven by specific mutations; patient-derived organoids, which preserve key molecular and histopathological features of the original tumors; and assembloids, which are designed to model tumor-microenvironment interactions. Together, these systems provide a human cell-relevant framework for investigating glioma biology, tumor-microenvironment crosstalk, and therapeutic responses and resistance. In this review, we provide a comprehensive overview of the spectrum of glioma organoid models, recognizing that different systems offer distinct and complementary strengths, and we offer practical guidance for selecting appropriate models and analytical readouts based on specific basic and translational research objectives. To address increasing methodological heterogeneity and fragmented terminology, we propose a foundational nomenclature framework for glioma organoid models to improve clarity and communication within the field. We highlight applications in technically challenging subtypes, including isocitrate dehydrogenase (IDH)-mutant gliomas and diffuse midline gliomas (DMGs). We also discuss key challenges-including scalability, standardization, microenvironment fidelity, and vascularization-and emerging innovations addressing these limitations. Finally, we call for greater collaboration and standardization within the glioma organoid community to accelerate the integration of organoid models into translational pipelines to redefine and refine preclinical modeling in neuro-oncology.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Hubert CG, Read RD, Miller TE, et al. Modeling gliomas with organoids: Classification, fidelity, and guidelines for translational neuro-oncology. Neuro Oncol. 2026. PMID: 42015385. doi:10.1093/neuonc/noag085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。